TrialClinical pharmacokinetics2025

Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.

Tommy Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.